Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
University of Ulm
University of Wisconsin, Madison
Pfizer
Werewolf Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
University of California, San Diego
University of California, San Diego
BeiGene
Scripps Translational Science Institute
Trishula Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Thomas Jefferson University
Celgene
Intensity Therapeutics, Inc.
Juno Therapeutics, a Subsidiary of Celgene
Pfizer
Takeda
EpicentRx, Inc.
National Cancer Institute (NCI)
AbbVie
Altor BioScience
Amgen
University of Virginia
Nordic Nanovector
Servier
Sumitomo Pharma America, Inc.
Servier
Eisai Inc.
AbbVie
Asana BioSciences
Duke University
Bristol-Myers Squibb
Molecular Templates, Inc.
Takeda
GlaxoSmithKline
Cancer Research UK
miRagen Therapeutics, Inc.
Institut Bergonié
Roswell Park Cancer Institute
PharmaMar
Children's Oncology Group
Merck Sharp & Dohme LLC
Takeda
Spectrum Pharmaceuticals, Inc
University of California, San Diego
University of California, San Diego
Novartis
Novartis
Helsinn Therapeutics (U.S.), Inc